Clinical trial · Observational
Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients
Effect of Thalidomide, Carmofur and Compound Mylabris Capsules (TCC) Cocktail Combined With Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone on Survival in Patients With Unresectable Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with conventional Transarterial Chemoembolization (TACE) for the treatment of patients with unresectable Hepatocellular Carcinoma (HCC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Cancer (HCC) | Hepatocellular Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carmofur | Drug | — | UNRESOLVED |
| compound mylabris capsule | Drug | — | UNRESOLVED |
| TACE | Procedure | — | UNRESOLVED |
| Thalidomide (50mg) | Drug | Thalidomide | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- TACE+cocktail
- description
- Patients in the TACE+cocktail group received TACE and took the combined oral medications daily, which consisted of thalidomide tablets, carmofur tablets , and compound mylabris capsule.
- interventionNames
- Drug: Thalidomide (50mg)
- Drug: carmofur
- Drug: compound mylabris capsule
- Procedure: TACE
- label
- TACE only
- description
- Patients in the TACE only group received only TACE treatment.
- interventionNames
- Procedure: TACE
Primary outcomes (1)
- measure
- Overall Survival (OS)
- timeFrame
- up to five years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients who met the HCC diagnostic criteria according to the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China. * patients underwent conventional TACE. * availability of complete medical records for data extraction and follow-up. Exclusion Criteria: * a history of previous or synchronous treatment for tumors such as radio frequency ablation (RFA) or systemic chemotherapy. * poor liver functions (Child-Pugh class C). * accompanying other life-threatening diseases.
References
Publications (0)
Data not yet available